Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marathon's High-Priced Window May Not Stay Open Long

Executive Summary

Ongoing trial is intended to compare the newly approved steroid Emflaza with prednisone in DMD for efficacy and safety.

Advertisement

Related Content

Before Price Controversy, Emflaza Got Easy US Nod With Old But Good Enough Data
Shaping A Shkreli Bill: Voucher Abuse Solution May Stumble On FDA Effects
Patient-Centered Promotion? Marathon's Non-Launch Of Emflaza Illustrates Challenge Of New Era
Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?
Drug Pricing Bill May Make Six-Month ANDA Review Slower Than Eight-Month Review
Pharma’s Pricing Debate Splinters As US Political Confrontation Looms
Sarepta Snaps Up Gene Therapy Approaches to DMD
Anthem Denies Coverage For Eteplirsen, Citing Lack Of Clinical Efficacy
Priority Review Vouchers Appear To Be Dropping In Price
Handling Drug Price Spikes: A Sad Place To Be

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098223

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel